Orthocell (ASX:OCC) submitted a medical device license application in Canada for its nerve repair product Remplir, according to a Monday Australian bourse filing.
The company expects the product to be approved in Canada in the second half of 2025.
It is planning to submit regulatory applications in Thailand in the March quarter, in the UK and the European Union in the September quarter, and in Brazil in the December quarter.
It is also evaluating Southeast Asian and Latin American markets.
It added that it expects US Food and Drug Administration approval in March or early April. Preparations for a market launch in the US are underway.
The company's shares fell past 3% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。